Introduction Sickle cell anemia has many sequelae that result in emergency department (ED)
use, but a minority of patients with sickle cell disease are frequent utilizers and make up …

Background Although nitric oxide based therapeutics have been shown in preclinical models
to reduce vaso-occlusive events and improve cardiovascular function, a clinical trial of a …

Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity
and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy…

Introduction: Previous studies have shown that cannabis use is common in adults with sickle
cell disease (SCD), and that many patients report using cannabis to treat pain. Methods: We …

More than one-third of adults with sickle cell disease (SCD) report using cannabis-based
products. Many states list SCD or pain as qualifying conditions for medical marijuana, but there …

Background In the late nineteenth and early twentieth centuries, cannabis in the United
States was mostly restricted to medical use, including for the management of pain, migraines, …

In 2019 voxelotor was approved by the United States Food and Drug Administration for the
treatment of sickle cell disease (SCD) in patients≥ 16 years. The HOPE trial showed that …

Until recently, there were few therapies which directly targeted red cell sickling. However, a
novel agent, voxelotor, has demonstrated its ability to increase hemoglobin levels by …

BACKGROUND Despite the clinical significance of red blood cell (RBC) alloantibodies,
there are currently no laboratory tests available to predict which patients may be at risk of …

Introduction White Blood Cell (WBC) count, %HbF, and serum creatinine (Cr), have been
identified as markers for increased mortality in sickle cell anemia (SCA) but no studies have …